The Global Market and Future Outlook for Neurodegenerative Disorder Therapies 2007
Overview
With a market size of US$14.5 billion in 2005 and an anticipated value of US$16.5 billion in 2006, the neurodegenerative market represents a valuable, fast-growing opportunity in the pharma/biotech industry. An increase in the number of aged people, increased life expectancy, unmet clinical needs together with advances in treatments of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease will continue to contribute to the expansion of the global market.
This report provides an insight into the neurodegenerative market, neurotherapeutic drugs currently available, and upcoming products. This report specifically focuses on key CNS diseases, such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, amyotrophic lateral sclerosis, Huntington’s disease, and neuropathies. Profiles of leading companies that are active in R&D in these areas are included.
The report presents, in detail, an overview of the current global market for neurodegenerative drugs for selected neurological diseases, including currently marketed and forthcoming neurotherapeutic products. Market analysis and assessment for key neurodegenerative therapies is done across major pharmaceutical markets in United States (US)/North America, Europe and Japan.
Key features of this report:
- Statistical information for selected neurological diseases
- Overview of the disease, key therapies, market size and growth, market composition by region, as well as market outlook and forecast
- Global sales figures for key neurodegenerative therapies
- Financial forecasts by disease and key product
- Description of neurotherapeutic products currently on the market, including a description of products in the pipeline
- Company profiles of major pharmaceutical providers active in R&D in these areas
- The report also deals with factors affecting growth, new drug therapies, and clinical research in the completion stages.
The diseases/conditions addressed in the report include:
- Alzheimer’s disease
- Parkinson’s disease
- Multiple sclerosis
- Amyotrophic lateral sclerosis
- Huntington’s disease
- Neuropathies
Table of Contents
- Table of Contents
- 1Executive Summary
- 1.1Report Scope
- 1.2Definitions
- 1.2.1Alzheimer’s Disease
- 1.2.2Parkinson’s Disease
- 1.2.3Multiple Sclerosis
- 1.2.4Amyotrophic Lateral Sclerosis
- 1.2.5Huntington’s Disease
- 1.2.6Neuropathies
- 1.3Report Methodology
- 1.4The Market
- 1.5Market Composition
- 1.6Competitive Profiles
- 1.7Factors to Growth
- 2The Market
- 2.1Global Pharmaceutical Market
- 2.2Global Neurodegenerative Market
- 2.3Market Size and Growth
- 2.4Market Composition
- 2.5US/North American Market
- 2.5.1Overview
- 2.5.2US Neurodegenerative Market
- 2.5.3Canadian Neurodegenerative Market
- 2.5.4Regulatory Scenario
- 2.6European Market
- 2.6.1Overview
- 2.6.2Regulatory Scenario
- 2.7Japanese Market
- 2.7.1Overview
- 2.7.2Japanese Neurodegenerative Market
- 2.7.3Regulatory Scenario
- 3Market Composition: Alzheimer’s Disease
- 3.1Overview
- 3.2Risk Factors
- 3.3Symptoms
- 3.4Therapies
- 3.5Market Size and Growth
- 3.6Market Composition
- 3.7By Region
- 3.8Major Players
- 3.9Anti-Alzheimer’s Disease Products
- 3.9.1AChE inhibitors
- 3.9.2NMDA Antagonists
- 3.10Incidence of Alzheimer’s Disease
- 3.11In the Pipeline
- 3.12Looking Ahead
- 3.13Key Clinical Trials
- 3.14Key Emerging Therapies
- 3.15Research and Development Trends
- 4Market Composition: Parkinson’s Disease
- 4.1Overview
- 4.2Risk Factors
- 4.3Symptoms
- 4.4Therapies
- 4.5Market Size and Growth
- 4.6Market Composition by Region
- 4.7Major Players
- 4.8Anti-Parkinson’s Disease Products
- 4.8.1Anticholinergics
- 4.8.2COMT Inhibitors
- 4.8.3Combination Anti-Parkinson’s Agents
- 4.8.4Dopamine Receptor Agonists
- 4.8.5Carbidopa Levodopa Preparations
- 4.8.6MAO-B inhibitors
- 4.8.7Amantadine
- 4.9Incidence and Prevalence of Parkinson’s Disease
- 4.10In the Pipeline
- 4.11Looking Ahead
- 4.12Key Clinical Trials
- 4.13Key Emerging Therapies
- 4.14Key Types of Therapies in Development
- 5Market Composition: Multiple Sclerosis
- 5.1Overview
- 5.2Risk Factors
- 5.3Symptoms
- 5.4Therapies
- 5.5Market Size and Growth
- 5.6Market Composition
- 5.7Major Players
- 5.8Multiple Sclerosis Products
- 5.8.1Avonex
- 5.8.2Betaseron
- 5.8.3Rebif
- 5.8.4Copaxone
- 5.8.5Novantrone
- 5.8.6Symptomatic Relief
- 5.9Incidence of Multiple Sclerosis
- 5.10In the Pipeline
- 5.11Looking Ahead
- 5.12Key Emerging Therapies
- 5.13Key Late-Stage Clinical Therapeutics
- 5.14Key Clinical Trials
- 6Market Composition: Amyotrophic Lateral Sclerosis
- 6.1Overview
- 6.2Risk Factors
- 6.3Symptoms
- 6.4Therapies
- 6.5Major Players
- 6.6Anti-Amyotrophic Lateral Sclerosis Products
- 6.7Incidence of Anti-Amyotrophic Lateral Sclerosis
- 6.8In the Pipeline
- 6.9Key Emerging Therapies
- 6.10Key Clinical Trials
- 7Market Composition: Huntington’s Disease
- 7.1Overview
- 7.2Risk Factors
- 7.3Symptoms
- 7.4Therapies
- 7.5Market Size and Growth
- 7.6Market Composition by Region
- 7.7Major Players
- 7.8Anti-Huntington’s Disease Products
- 7.8.1Neuroleptics
- 7.8.2Benzodiazepines
- 7.9Incidence of Huntington’s Disease
- 7.10In the Pipeline
- 7.11Key Emerging Therapies
- 8Neuropathies
- 8.1Overview
- 8.2Risk Factors
- 8.3Symptoms
- 8.4Therapies
- 8.5Market Size and Growth
- 8.6Anti-Neuropathies Products
- 8.6.1Anticonvulsants
- 8.6.2Antidepressants
- 8.6.3Analgesics
- 8.6.4Others
- 8.7Incidence of Neuropathies
- 8.8In the Pipeline
- 8.9Looking Ahead
- 8.10Key Emerging Therapies
- 8.11Key Clinical Trials
- 9Competitive Profiles
- 9.1Amarin
- 9.1.1Product Pipeline
- 9.1.2Key Financials
- 9.2AstraZeneca
- 9.2.1Product Portfolio
- 9.2.2Product Pipeline
- 9.2.3Key Financials
- 9.3Avanir
- 9.3.1Product Portfolio
- 9.3.2Product Pipeline
- 9.3.3Key Financials
- 9.4Avigen
- 9.4.1Product Pipeline
- 9.4.2Key Financials
- 9.5Biogen Idec
- 9.5.1Product Portfolio
- 9.5.2Product Pipeline
- 9.5.3Key Financials
- 9.6Boehringer Ingelheim
- 9.6.1Product Portfolio
- 9.6.1.1Key Financials
- 9.6.1Product Portfolio
- 9.7Daiichi Sankyo
- 9.7.1Product Portfolio
- 9.7.2Key Financials
- 9.8Eisai
- 9.8.1Product Portfolio
- 9.8.2Product Pipeline
- 9.8.3Key Financials
- 9.9Elan
- 9.9.1Product Portfolio
- 9.9.2Product Pipeline
- 9.9.3Key Financials
- 9.10Eli Lilly
- 9.10.1Product Portfolio
- 9.10.2Product Pipeline
- 9.10.3Key Financials
- 9.11Forest Laboratories
- 9.11.1Product Portfolio
- 9.11.2Product Pipeline
- 9.11.3Key Financials
- 9.12Genzyme
- 9.12.1Product Pipeline
- 9.12.2Key Financials
- 9.13GlaxoSmithKline
- 9.13.1Product Portfolio
- 9.13.2Product Pipeline
- 9.13.3Key Financials
- 9.14Guilford Pharmaceuticals/MGI Pharma
- 9.14.1Product Pipeline
- 9.14.2Key Financials
- 9.15IVAX
- 9.15.1Product Portfolio
- 9.15.2Key Financials
- 9.16Johnson & Johnson
- 9.16.1Product Portfolio
- 9.16.2Product Pipeline
- 9.16.3Key Financials
- 9.17Kyowa Hakko Kogyo
- 9.17.1Product Portfolio
- 9.17.2Product Pipeline
- 9.17.3Key Financials
- 9.18Lundbeck
- 9.18.1Product Portfolio
- 9.18.2Product Pipeline
- 9.18.3Key Financials
- 9.19Merck KGaa
- 9.19.1Product Portfolio
- 9.19.2Product Pipeline
- 9.19.3Key Financials
- 9.20Mitsubishi Pharma
- 9.20.1Product Portfolio
- 9.20.2Product Pipeline
- 9.20.3Key Financials
- 9.21Novartis
- 9.21.1Product Portfolio
- 9.21.2Product Pipeline
- 9.21.3Key Financials
- 9.22Pain Therapeutics
- 9.22.1Product Pipeline
- 9.22.2Key Financials
- 9.23Pfizer
- 9.23.1Product Portfolio
- 9.23.2Product Pipeline
- 9.23.3Key Financials
- 9.24Prestwick Pharmaceuticals
- 9.24.1Product Pipeline
- 9.25Roche
- 9.25.1Product Pipeline
- 9.25.2Key Financials
- 9.26Sanofi-Aventis
- 9.26.1Product Portfolio
- 9.26.2Product Pipeline
- 9.26.3Key Financials
- 9.27Schering AG
- 9.27.1Product Portfolio
- 9.27.2Product Pipeline
- 9.27.3Key Financials
- 9.28Shire Plc
- 9.28.1Product Portfolio
- 9.28.2Product Pipeline
- 9.28.3Key Financials
- 9.29Solvay
- 9.29.1Product Portfolio
- 9.29.2Product Pipeline
- 9.29.3Key Financials
- 9.30Takeda
- 9.30.1Product Pipeline
- 9.30.2Key Financials
- 9.31Teva
- 9.31.1Product Portfolio
- 9.31.2Product Pipeline
- 9.31.3Key Financials
- 9.32Valeant Pharmaceuticals
- 9.32.1Product Portfolio
- 9.32.2Product Pipeline
- 9.32.3Key Financials
- 9.33Wyeth
- 9.33.1Product Portfolio
- 9.33.2Product Pipeline
- 9.33.3Key Financials
- 9.1Amarin
- 10Factors to Growth
- 10.1Demographic
- 10.2Healthcare Spends
- 10.3Disease Conditions
- 10.4Patent Expiry of Popular Products
- 10.5New Drug Therapies
- 10.6Growth of Generics
- 10.6.1Key Facts about Generics
- 10.6.2Generics in the Future
- Appendix A: Patent Expiries
- Appendix B: Alzheimer’s Disease Clinical Research
- Appendix C: Parkinson’s Disease Clinical Research
- Appendix D: Multiple Sclerosis Clinical Research
- Appendix E: Amyotrophic Lateral Sclerosis Clinical Research
- Appendix F: Huntington’s Disease Clinical Research
- Appendix G: Neuropathies Clinical Research
- Appendix H: Notes on Related Dementias (RD)
- Appendix I: Notes on Parkinsonism
- Tables
- Table 10.2 World Market for Neurodegenerative Drug, 2006-2010 ($ mn)
- Table 2.1 United States Health Insurance Expenditures by Type of Expenditure
- Table 2.2 Visits made to physicians by age group and sex (%)
- Table 2.3 Usage of Prescription Drugs by Type
- Table 2.4 Cholinesterase Inhibitors Expenditure per 1000 Persons Aged 65
- Table 3.1 World Market for Alzheimer’s Disease by Region, 2005 ($)
- Table 3.2 Global Sales (2001 - 2005) - Aricept ($ mn)
- Table 3.3 Global Sales Forecast (2006-2010) - Aricept ($ mn)
- Table 3.4 Global Sales (2001 - 2005) - Exelon ($ mn)
- Table 3.5 Global Sales Forecast (2006-2010) - Exelon ($ mn)
- Table 3.6 Global Sales (2001 - 2005) - Reminyl ($ mn)
- Table 3.7 Global Sales Forecast (2006-2010) - Reminyl ($ mn)
- Table 3.8 Global Sales Forecast (2004-2010) - Namenda/Ebixia ($ mn)
- Table 3.9 Alzheimer’s Disease Incidence
- Table 3.10 Prevalence of Alzheimer’s Disease - (Million)
- Table 3.11 Alzheimer’s Disease Pipeline
- Table 3.12 World Market for Anti-Alzheimer’s Products, 2006-2010 ($ mn)
- Table 4.1 World Market for Parkinson’s Disease by Region, 2005 ($)
- Table 4.2 Global Sales Forecast - Comtan ($ mn)
- Table 4.3 Global Sales Forecast - Tasmar ($mn)
- Table 4.4 Global Sales Forecast - Stalevo ($ mn)
- Table 4.5 Global Sales Forecast - Mirapex/Sifrol ($mn)
- Table 4.6 Global Sales - Requip ($ mn)
- Table 4.7 Global Sales Forecast - Requip ($ mn)
- Table 4.8 Prevalence of Parkinson’s Disease (mn)
- Table 4.9 Parkinson’s Disease Pipeline
- Table 4.10 World Market for Anti-Parkinson’s Products, 2006-2010 ($ mn)
- Table 4.11 Available and Emerging Drugs for Parkinson’s Disease
- Table 5.1 Global Sales - Avonex ($ mn)
- Table 5.2 Global Sales Forecast - Avonex ($ mn)
- Table 5.3 Global Sales - Betaseron ($ mn)
- Table 5.4 Global Sales Forecast - Betaseron ($ mn)
- Table 5.5 Global Sales - Rebif ($ mn)
- Table 5.6 Global Sales forecast - Rebif ($ mn)
- Table 5.7 Global Sales - Copaxone ($ mn)
- Table 5.8 Global Sales Forecast - Copaxone ($ mn)
- Table 5.9 Multiple Sclerosis Pipeline
- Table 5.10 Forecast of Multiple Sclerosis Drug Market, 2006-2010 ($ mn)
- Table 6.1 Amyotrophic Lateral Sclerosis Pipeline
- Table 7.1 Global Sales Forecast - Risperdal ($ mn)
- Table 7.2 Huntington’s Disease Pipeline
- Table 8.1 Global Sales - Tegretol ($ mn)
- Table 8.2 Global Sales Forecast - Tegretol ($ mn)
- Table 8.3 Global Sales - Neurontin ($ mn)
- Table 8.4 Global Sales Forecast - Neurontin ($ mn)
- Table 8.5 Global Sales Forecast - Cymbalta ($ mn)
- Table 8.6 Global Sales Forecast - Lyrica ($ mn)
- Table 8.7 Neuropathies Pipeline
- Table 8.8 Global Neuropathic Pain Market ($ mn)
- Table 9.1 Companies Active in Neurodegenerative Research, by Condition
- Table 10.1 Major US Patent Expiries 2005-2007
- Graphs
- Graph 2.1 Global Pharmaceutical Sales 2001-2005
- Graph 2.2 Global Pharmaceutical Sales by Region, 2005**
- Graph 2.3 Leading Products by Global Pharmaceutical Sales, 2005**
- Graph 2.4 Leading Therapy Classes by Global Pharmaceutical Sales, 2005**
- Graph 2.5 Number of Parkinson Drug Prescriptions Dispensed
- Graph 2.6 Recommended Drug Therapies for Parkinson’s Disease
- Graph 3.1 World Market for Alzheimer’s Disease by Region, 2005 (%)
- Graph 3.2 Alzheimer’s Disease Prevalence
- Graph 4.1 World Market for Parkinson’s Disease by Region, 2005 (%)
- Graph 5.1 Market Share of Leading Multiple Sclerosis Therapies, 2005
- Graph 8.1 Top Causes of Pain
- Graph 10.1 Percentage Increase in Age 60 and Over by Region, 2000-2050
- Graph 10.2 World Aging Trends
- Graph 10.3 Health Spending in Organization for Economic Co-operation and
- Development (OECD) Countries as % of GDP, 2003
- Graph 10.4 Government Expenditure on Health
- Graph 10.5 U.S. Growth of Generics, 1984-2005
- Graph 10.6 U.S. Generics vs. Brand-Name Pharmaceuticals Sales, 2005
- Graph 10.7 Generic Drug Sales in U.S. (projected)
Other users found this report page using the following search terms: neuroprotection neurodegeneration neurodegenerative parkinsons lyricaglobalsalesregion
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.